Last reviewed · How we verify
Centhaquine + Standard Treatment
Centhaquine + Standard Treatment is a S1P receptor agonist Small molecule drug developed by Pharmazz, Inc.. It is currently in Phase 3 development for Septic shock (in combination with standard treatment), Hemorrhagic shock (in combination with standard treatment). Also known as: PMZ-2010.
Centhaquine is a first-in-class small molecule that activates sphingosine-1-phosphate receptors to improve microcirculation and reduce cellular injury in shock states.
Centhaquine is a first-in-class small molecule that activates sphingosine-1-phosphate receptors to improve microcirculation and reduce cellular injury in shock states. Used for Septic shock (in combination with standard treatment), Hemorrhagic shock (in combination with standard treatment).
At a glance
| Generic name | Centhaquine + Standard Treatment |
|---|---|
| Also known as | PMZ-2010 |
| Sponsor | Pharmazz, Inc. |
| Drug class | S1P receptor agonist |
| Target | Sphingosine-1-phosphate receptor 1 (S1P1) |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Shock Management |
| Phase | Phase 3 |
Mechanism of action
Centhaquine binds to sphingosine-1-phosphate (S1P) receptors, particularly S1P1, which enhances endothelial barrier function, reduces vascular permeability, and improves tissue perfusion. By stabilizing the microvasculature and reducing inflammatory cell infiltration, it mitigates organ damage in septic and hemorrhagic shock when combined with standard supportive care.
Approved indications
- Septic shock (in combination with standard treatment)
- Hemorrhagic shock (in combination with standard treatment)
Common side effects
- Hypertension
- Bradycardia
- Headache
- Increased liver enzymes
Key clinical trials
- A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients (PHASE4)
- A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent (PHASE3)
- Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock (PHASE3)
- PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Centhaquine + Standard Treatment CI brief — competitive landscape report
- Centhaquine + Standard Treatment updates RSS · CI watch RSS
- Pharmazz, Inc. portfolio CI
Frequently asked questions about Centhaquine + Standard Treatment
What is Centhaquine + Standard Treatment?
How does Centhaquine + Standard Treatment work?
What is Centhaquine + Standard Treatment used for?
Who makes Centhaquine + Standard Treatment?
Is Centhaquine + Standard Treatment also known as anything else?
What drug class is Centhaquine + Standard Treatment in?
What development phase is Centhaquine + Standard Treatment in?
What are the side effects of Centhaquine + Standard Treatment?
What does Centhaquine + Standard Treatment target?
Related
- Drug class: All S1P receptor agonist drugs
- Target: All drugs targeting Sphingosine-1-phosphate receptor 1 (S1P1)
- Manufacturer: Pharmazz, Inc. — full pipeline
- Therapeutic area: All drugs in Critical Care / Shock Management
- Indication: Drugs for Septic shock (in combination with standard treatment)
- Indication: Drugs for Hemorrhagic shock (in combination with standard treatment)
- Also known as: PMZ-2010
- Compare: Centhaquine + Standard Treatment vs similar drugs
- Pricing: Centhaquine + Standard Treatment cost, discount & access